Sagimet Biosciences to Present Additional Biomarker Phase 2 Data on Denifanstat (TVB-2640) in NASH Patients at DDW 2022

SAN MATEO, Calif.--(BUSINESS WIRE)-- #Clinicaltrials--Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally discovered, selective fatty acid synthase (FASN) inhibitors, announced today that it will present expanded clinical biomarker data on denifanstat (formerly known as TVB-2640), its lead product candidate for the potential treatment for nonalcoholic...

Click to view original post